On Friday 3rd March, Dr Jan Van Emelen, Innovation Director at Neutral Mutualities presented on “Mutualities and pharmaceutical industry: a new relationship?”. Access to new, often very expensive medications is a hot topic and our speaker discussed the role of the mutualities in this process, using new models for disease management. He shared ideas on our potential interaction with this process as pharmaceutical physicians.
By Annette Gardner, PhD, MPH
Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco
The Patient Protection and Affordable Care Act (ACA) is an opportunity to coordinate care among health care providers and transform local nets into seamless systems of care. The study conducted by Dr. Annette Gardner, PhD, MPH, at the Philip R. Lee Institute for Health Policy Studies, UCSF, shows safety net integration activities in five counties—Contra Costa, Humboldt, San Diego, San Joaquin, and San Mateo—suggests much progress has been made to this end in these counties.
This Report describes the factors that affect a local safety net's ability to develop integrated delivery systems and lessons learned from the implementation of 30 safety net integration "best practices".
"eHealth Literacy, Getting Started" was presented at the Center for Health Literacy Conference 2011: Plain Talk in Complex Times by Shannah Koss, MPP, President, Koss on Care LLC (Principal, MAXIMUS eHealth Literacy Collaborative).
Description: Learn how to design and develop a consumer-oriented strategy and foundation for outreach, education, and engagement in the early stages of your state or community's health IT and reform programs. Find out about funding options. Share challenges and solutions for integrating eHealth literacy tools and resources into the emerging health IT infrastructure.
By Annette Gardner, PhD, MPH
Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco
The Patient Protection and Affordable Care Act (ACA) is an opportunity to coordinate care among health care providers and transform local nets into seamless systems of care. The study conducted by Dr. Annette Gardner, PhD, MPH, at the Philip R. Lee Institute for Health Policy Studies, UCSF, shows safety net integration activities in five counties—Contra Costa, Humboldt, San Diego, San Joaquin, and San Mateo—suggests much progress has been made to this end in these counties.
This Report describes the factors that affect a local safety net's ability to develop integrated delivery systems and lessons learned from the implementation of 30 safety net integration "best practices".
"eHealth Literacy, Getting Started" was presented at the Center for Health Literacy Conference 2011: Plain Talk in Complex Times by Shannah Koss, MPP, President, Koss on Care LLC (Principal, MAXIMUS eHealth Literacy Collaborative).
Description: Learn how to design and develop a consumer-oriented strategy and foundation for outreach, education, and engagement in the early stages of your state or community's health IT and reform programs. Find out about funding options. Share challenges and solutions for integrating eHealth literacy tools and resources into the emerging health IT infrastructure.
Full-day workshop held by Fabio Sergio and Thomas Sutton on November 30 2009 at the Mobile Healthcare Industry Summit, in London (www.mobilehealthcareindustrysummit.com).
"How can your organization make the most of the emerging opportunities presented by mobile healthcare?
How do you design successful m-Health solutions?
In this full-day workshop, frog design will help you answer these questions and provide you with a toolkit to drive your company's m-Health strategy."
Patient-Centric Privacy: Envisioning Collaboration Between Payers, Providers...Tyrone Grandison
Protection of personal healthcare information (PHI) has been as a significant hindrance to the acceptance, adoption and continued use of healthcare information technology (HIT). As nations and corporations encourage innovation in the healthcare sector for better outcomes for all its stakeholders, they are proceeding under a latent assumption – the equation of data stewardship with data ownership. This notion relegates the patient to the role of information provider and empowers infrastructure owners with data ownership rights. In this paper, we introduce Patient-Centric Privacy, which refers to 1) the recognition that patients are a fundamental and integral part of the disclosure, access and use processes, and 2) to the ability of the patient to control the release of their healthcare information.
Katrina Percy: Working with partners to deliver high quality health and socia...The King's Fund
Katrina Percy, Chief Executive of Southern Health NHS Foundation Trust, talks about the health system in Hampshire and the key elements of Southern Health’s integrated care strategy.
Full-day workshop held by Fabio Sergio and Thomas Sutton on November 30 2009 at the Mobile Healthcare Industry Summit, in London (www.mobilehealthcareindustrysummit.com).
"How can your organization make the most of the emerging opportunities presented by mobile healthcare?
How do you design successful m-Health solutions?
In this full-day workshop, frog design will help you answer these questions and provide you with a toolkit to drive your company's m-Health strategy."
Patient-Centric Privacy: Envisioning Collaboration Between Payers, Providers...Tyrone Grandison
Protection of personal healthcare information (PHI) has been as a significant hindrance to the acceptance, adoption and continued use of healthcare information technology (HIT). As nations and corporations encourage innovation in the healthcare sector for better outcomes for all its stakeholders, they are proceeding under a latent assumption – the equation of data stewardship with data ownership. This notion relegates the patient to the role of information provider and empowers infrastructure owners with data ownership rights. In this paper, we introduce Patient-Centric Privacy, which refers to 1) the recognition that patients are a fundamental and integral part of the disclosure, access and use processes, and 2) to the ability of the patient to control the release of their healthcare information.
Katrina Percy: Working with partners to deliver high quality health and socia...The King's Fund
Katrina Percy, Chief Executive of Southern Health NHS Foundation Trust, talks about the health system in Hampshire and the key elements of Southern Health’s integrated care strategy.
NEHTA and Department of Health & Ageing hosted a Software Developer Conference in conjunction with CHIK's Health-e-Nation 2012 conference in March 2012.
Mick Reid of McKinsey & Co took part in the “What’s in it for me?” panel describing the process and outcomes of Cairns health region study.
Dr azilina 1 care for ph conference 12july2011 11july 2011EyesWideOpen2008
Slide 18 shows the implementation process of 1Care. In phases 1 to 3 the name 1Care doesn't even appear but it is part of the process.
The MOH Deputy Director General, Datuk Dr Noor Hisham Abdullah has confirmed that 1Care is currently in phase 1 & 2 of implementation.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Sickness Funds and the Pharmaceutical Industry: a New Relationship?
1. Sickness Funds and the Pharmaceutical
Industry: a New Relationship?
Jan Van Emelen
Director Innovation
02.03.2012
2. Who are the Independant « health »
insurance funds?
18% of Belgian Market
Permanent growth
Compulsory and complementary health insurance
Services of social economy
Information on health, healthcare and insurance issues.
Union and 7 health insurance funds
Innovation oriented, chronic disease management
2
Réunion - Date
3. Our Values
Independent health insurance funds are
Independent and political neutral
Sceptical but constructive
Transparent
Dynamic and innovative
Rational and scientific
Competition but solidarity
3
Réunion - Date
4. 1. Context : shifts
1. Epidemiology
• Chronic conditions leading cause of morbidity & mortality ,
cost driver
• Demographic - Long Term care : budget and workforce
• Globalisation and warming up : new diseases
2. Economy
• Labor shortage : need for efficiency
• Budget restrictions – need for efficiency
• Mandating
3. Society
• Quality and safety : need validation system
• P4P - More homecare instead of hospitalisation
• Prevention - Individual care – patient empowerment
4
Réunion - Date
5. Chronic diseases anno 2010
(Cfr . Reinhardt Busse – European Observatory)
Burden :
Epidemiologic
Economic
How to tackle :
Prevention
Disease Management
Integrated care
Challenges
Technical innovation : Pharmaceutical, IT
Organisation innovation : model
Financing innovation: model with incentives
5
Réunion - Date
6. Context in HC system
Functions Services
Governance Accessibility
Quality of Care
HR Management Service delivery
Financial
contribution
Financing system
6
Réunion - Date
7. Context in health care system
Functions
Poliitcal,
Willingness
Datamanagement, Governance
Corporate governance
Care model
Acute +
HR Management Service delivery
Role Chronic
Training, Prevention
Agreement
Financing system
Budget (macro)
Financial model
7
Réunion - Date
8. Vision
VISION : Integrated customised care
• Integrated : creating efficiency
1. primary & secondary care :
2. medical care and social care
• Customized
1. Focusgroups in each lifetime period
2. Stratified medecines
8
Réunion - Date
9. Consequences
Paradigm shift: new medical model
Paradigm shift: new financial model in support
Role and functions of stakeholders in change
Partnerships between insurers, health care
providers, industry, authorities.
RM, DM, CM and public health initiative for elderly
people
9
Réunion - Date
10. 2. MLOZ innovation in Belgium
New type of innovative insurance : Chronic conditions and
dental care : Dentalia+
Pilotprojects education-coaching : zorgTV
Creation of Consortium DM – EU evolution
Prejudicial question privacycommission – new prevention
systems
RCT – COACHING diabetes type 2
PHR
Planning : coaching of patients with other diseases
10
Réunion - Date
16. 3. MLOZ at EU level : AIM
Disease Management working group
1. Exchange of information - workshops
2. Field visits- Ehtel (Odensee, Schotland NHS)
3. Mandate for developing
- EU project – foundations
- Establishment research institute and service
centre
16
Réunion - Date
17. Joint Venture
Epposi : Model for chronic care
- Public health infrastructure
- Patient empowerment
- Practice level (self-management, decision support, delivery
system, clinical information system,
- Community linkages
17
Réunion - Date
18. Target
Target: Enable Modus Operandi for CDM -
EU funded project – proposal in answer to 3d call of
the EU Public Health (support EIP)
- Consensus project : building the foundation for
innovative change management : work packages
- Establish EU independant centre (structure tbd)
Research
Services
validation
18
Réunion - Date
19. EU project
Foundations for change - deliverables :
1. Benchmarking system for management processes - strategy
2. Care managament pathways protocols and RA
3. Design business models including financial models
4. Design change models toward chronic conditions
management
5. Development and pilots of products and services
6. Organisational sustainable Business plan
With 11 related Work packages (vertical and horizontal)
19
Réunion - Date
20. Conclusion : invitation to partner
- Health care insurers
- Patients organisations
- Industry
- Health care providers
- Universities
20
Réunion - Date
21. l’Union Nationale des Mutualités Libres regroupe :
de Landsbond van de Onafhankelijke Ziekenfondsen groepeert :